HSPB1 and cancer: Targeting Hsp27 overexpression in different types of cancers has been shown promising (Rocchi et al., 2006; Cayado-Gutierrez et al., 2013; Lamoureux et al., 2014) but currently no clinical trial has passed phase III (Agensys, 2014).